ImmunityBio (IBRX) Research & Development (2014 - 2026)
ImmunityBio (IBRX) reported Research & Development of $600000.0 for Q1 2026, up 20.0% year-over-year from $500000.0 in Q1 2025, and down 25.0% quarter-over-quarter from $800000.0 in Q4 2025.
ImmunityBio (IBRX) Research & Development (2014 - 2026) Analysis & Trends
ImmunityBio (IBRX) has 13 years of Research & Development data on file, last reported at $600000.0 in Q1 2026.
- Research & Development for Q1 2026 came in at $600000.0, up 20.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.0 million (down 23.08% YoY), and the FY2025 annual result was $800000.0, down 75.76% from the prior year.
- Research & Development retreated to $600000.0 in Q1 2026 per IBRX's latest filing, from $800000.0 in the prior quarter.
- Over five years, Research & Development peaked at $79.3 million in Q1 2023 and troughed at -$178.6 million in Q4 2023.
- A 5-year average of $16.0 million and a median of $1.3 million in 2024 frame the typical range for Research & Development.
- The sharpest annual moves came in 2023 and 2024: Research & Development sank 407.58% in 2023, then surged 100.67% in 2024.
- A 5-year view of Research & Development shows it stood at $58.1 million in 2022, then slumped by 407.58% to -$178.6 million in 2023, then soared by 100.67% to $1.2 million in 2024, then tumbled by 33.33% to $800000.0 in 2025, then fell by 25.0% to $600000.0 in 2026.
- Business Quant data shows IBRX's Research & Development at $600000.0 in Q1 2026, $800000.0 in Q4 2025, and $600000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 4.32 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 15.66 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 626,092.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -101.30 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -2.30 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 1.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 357,444.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 961.60 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -58.00 Mn |
| 10 | ImmunityBio | 7.55 Bn | 7.17 Bn | 43.97 Mn | 600,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 600,000.00 |
| Dec 31, 2025 | 800,000.00 |
| Jun 30, 2025 | 600,000.00 |
| Mar 31, 2025 | 500,000.00 |
| Dec 31, 2024 | 1.20 Mn |
| Sep 30, 2024 | 600,000.00 |
| Jun 30, 2024 | 300,000.00 |
| Mar 31, 2024 | 1.40 Mn |
| Dec 31, 2023 | -178.63 Mn |
| Sep 30, 2023 | 48.40 Mn |
| Jun 30, 2023 | 53.17 Mn |
| Mar 31, 2023 | 79.26 Mn |
| Dec 31, 2022 | 58.08 Mn |
| Sep 30, 2022 | 71.61 Mn |
| Jun 30, 2022 | 63.08 Mn |
| Mar 31, 2022 | 55.38 Mn |
| Dec 31, 2021 | 51.75 Mn |
| Sep 30, 2021 | 49.28 Mn |
| Jun 30, 2021 | 53.80 Mn |
| Mar 31, 2021 | 41.13 Mn |